21.71
-0.28 (-1.27%)
| Penutupan Terdahulu | 21.99 |
| Buka | 21.63 |
| Jumlah Dagangan | 109,173 |
| Purata Dagangan (3B) | 645,979 |
| Modal Pasaran | 1,398,382,336 |
| Harga / Jualan (P/S) | 19.79 |
| Harga / Buku (P/B) | 3.43 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Oct 2024 - 18 Oct 2024 |
| Margin Operasi (TTM) | -433.83% |
| EPS Cair (TTM) | -2.90 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -31.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.20% |
| Nisbah Semasa (MRQ) | 5.28 |
| Aliran Tunai Operasi (OCF TTM) | -97.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -56.77 M |
| Pulangan Atas Aset (ROA TTM) | -29.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -57.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Nurix Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.80 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.45% |
| % Dimiliki oleh Institusi | 97.78% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 35.00 (BTIG, 61.22%) | Beli |
| 35.00 (HC Wainwright & Co., 61.22%) | Beli | |
| 35.00 (BMO Capital, 61.22%) | Beli | |
| 35.00 (UBS, 61.22%) | Beli | |
| Median | 35.00 (61.22%) | |
| Rendah | 29.00 (Needham, 33.58%) | Beli |
| Purata | 33.80 (55.69%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 22.40 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Dec 2024 | 35.00 (61.22%) | Beli | 21.31 |
| 21 Oct 2024 | 30.00 (38.19%) | Beli | 25.48 | |
| BTIG | 10 Dec 2024 | 35.00 (61.22%) | Beli | 22.06 |
| Needham | 10 Dec 2024 | 29.00 (33.58%) | Beli | 22.06 |
| 06 Nov 2024 | 29.00 (33.58%) | Beli | 27.00 | |
| BMO Capital | 06 Dec 2024 | 35.00 (61.22%) | Beli | 21.37 |
| UBS | 24 Oct 2024 | 35.00 (61.22%) | Beli | 25.22 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| RING CHRISTINE | - | 19.51 | -5,760 | -112,378 |
| Jumlah Keseluruhan Kuantiti Bersih | -5,760 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -112,378 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 19.51 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RING CHRISTINE | Pegawai | 02 Jan 2025 | Jual automatik (-) | 5,760 | 19.51 | 112,378 |
| RING CHRISTINE | Pegawai | 02 Jan 2025 | Pelaksanaan pilihan | 5,760 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |